跳转至内容

Dear Customer:

The current international situation is complex and volatile, and uncertain tariff policies may potentially impact our product prices. Given these uncertainties, we value your understanding regarding order-related matters.

If you decide to place an order during this period, we reserve the right to adjust the price based on the evolving situation. We understand that market changes may cause inconvenience. We will negotiate with you if there’s a significant price fluctuation due to tariff policy changes before the order’s actual delivery, and in such cases we may adjust or cancel the order as necessary.

We are planning system maintenance between Friday, Apr 18 at 9:00 PM CDT and Saturday, Apr 19 at 9:00 AM CDT. This will impact both web and offline transactions, including online orders, quotes, price and availability checks, and order status inquiries. We apologize for any inconvenience.

For important updates on recent policy changes, please click here for more details.

Merck
CN
  • Adventitial delivery of lentivirus-shRNA-ADAMTS-1 reduces venous stenosis formation in arteriovenous fistula.

Adventitial delivery of lentivirus-shRNA-ADAMTS-1 reduces venous stenosis formation in arteriovenous fistula.

PloS one (2014-04-16)
Evelyn C Nieves Torres, Binxia Yang, Bhaskar Roy, Rajiv Janardhanan, Akshaar Brahmbhatt, Ed Leof, Debabrata Mukhopadhyay, Sanjay Misra
摘要

Hemodialysis vascular access can develop venous neointimal hyperplasia (VNH) causing stenosis. Recent clinical and experimental data has demonstrated that there is increased expression of a disintegrin and metalloproteinase thrombospondin motifs-1 (ADAMTS-1) at site of VNH. The experiments outlined in the present paper were designed to test the hypothesis that targeting of the adventitia of the outflow vein of murine arteriovenous fistula (AVF) using a small hairpin RNA that inhibits ADAMTS-1 expression (LV-shRNA-ADAMTS-1) at the time of fistula creation will decrease VNH. At early time points, ADAMTS-1 expression was significantly decreased associated with a reduction in vascular endothelial growth factor-A (VEGF-A) and matrix metalloproteinase-9 (MMP-9) (LV-shRNA-ADAMTS-1 transduced vessels vs. controls). These changes in gene and protein expression resulted in favorable vascular remodeling with a significant increase in mean lumen vessel area, decrease in media/adventitia area, with a significant increase in TUNEL staining accompanied with a decrease in cellular proliferation accompanied with a reduction in CD68 staining. Collectively, these results demonstrate that ADAMTS-1 transduced vessels of the outflow vein of AVF have positive vascular remodeling.

材料
货号
品牌
产品描述

Sigma-Aldrich
MISSION® esiRNA, targeting human ADAMTS1
登录查看公司和协议定价
货号包装规格是否有货价格数量
20 μg
预计发货时间 July 10, 2025
详情...
CN¥3,096.05
50 μg
预计发货时间 July 10, 2025
详情...
CN¥5,521.27
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Adamts1
登录查看公司和协议定价
货号包装规格是否有货价格数量
20 μg
预计发货时间 July 10, 2025
详情...
CN¥3,096.05
50 μg
预计发货时间 July 10, 2025
详情...
CN¥5,521.21